CRVO Latest News

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

globenewswire.com — Apr 22, 2026

Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basa

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

globenewswire.com — Apr 7, 2026

Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial

Illumina, Inc. $ILMN Shares Sold by CIBC Private Wealth Group LLC

defenseworld.net — Mar 20, 2026

CIBC Private Wealth Group LLC cut its stake in Illumina, Inc. (NASDAQ: ILMN) by 4.

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology

globenewswire.com — Mar 19, 2026

New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer's disease (AD) co-pa

Head-To-Head Survey: Illumina (NASDAQ:ILMN) versus CervoMed (NASDAQ:CRVO)

defenseworld.net — Mar 19, 2026

Illumina (NASDAQ: ILMN - Get Free Report) and CervoMed (NASDAQ: CRVO - Get Free Report) are both medical companies, but which is the better stock? We